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cryptogenic stroke was significantly higher in the PFO group (18/50,36%) vs
control group (5/34, 15%), p < 0.04.
Conclusions: 1. The prevalence of PFO decreases from the neonate to the
adult.
2. There is a high prevalence of cryptogenic stroke among adults with PFO
who have suffered a cerebrovascular event.
3. These results provide a baseline for designing future prospective stud-
ies of PFO and CV events, and randomized trials to determine the impact of
PFO closure.
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1735-41 Characteristics of Patent Foramen Ovale in Stroke
Patients: Two-dimensional and Biplane Contrast
Transesophageal Study
Stefano De Castro, Domenico Cartoni, Maurizia Rasura 1, Sergio Beni,
Alexia Anzini 1, Monica Moschini Antinori. Francesco Pelliccia, Paride Giannantoni.
Dept. of Clinical Medicine, "IE Sapienza" University, Rome, Italy; 1 Dept. of
Neuroscience, "La Sapienza'" University. Rome, Italy
Transesophageal echocardiography (TEE) has detected an increased preva-
lence of Patent Foramen Ovale (PFO) in patients with unexplained stroke. In
order to evaluate the morphological characteristics of PFO, 130 consecutive
stroke patients were studied. Of these, 21 with PFO (16%) were identified by
saline contrast TEE (Gr.A). They were matched for age and sex with 25 con-
trols (Gr.B) who had also recently had ischemic stroke but no cardiac sources
of emboli detected by TEE.
On TEE we measured: diameter of fossa ova lis (DFO); separation between
septum primum and secundum (MaxSep); thickness, length and mobility of
the fossa ovale membrane. With saline contrast injection, the number of mi-
crobubbles appearing in left atrium were counted: mild «10 mb), moderate
(10-20 mb) and severe (>20 mb).
Compared with Group B, Group A showed increased MaxSep (p < 0.0001)
and membrane mobility (p < 0.001). In addition, the degree of right to left
shunt was directly correlated to the increased in MaxSep (mild vs severe; p
< 0.0001).
In conclusion, the morphological aspect of FO in patients with ischemic
stroke and PFO, is cha racterized by an increased separation between septum
primum and septum secundum and greater mobility of the FO membrane.
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Role of Patent Foramen Ovale and Deep Venous
Thrombosis in 220 Patients with Unexplained Stroke
or Transient Ischemic Attack: A Prospective
Transthoracic and Transesophageal
Echocardiographic Study
Harald Lethen, Franz Beck, Gerlinde Kahn, Rolf Schneider 1, Ulrich Sliwka 1,
Andreas Franke, Frank A. Flachskampf, Johannes Noth 1, Peter Hanrath. Med
KJimk I, RWTH Aachen, Germany; 1 Depf. Neurology!», RWTH Aachen, Germany
To evaluate the additional value of biplane transesophageal (TEE) compared
to transthoracic (TIE) echo and the role of patent foramen ovale IPFO) and
deep vein thrombosis (DVT) in the work-up of embolic events, patients (pts)
with presumed cardiac embolic stroke or transient ischemic attack (TIA) (neu-
rovascular etiology was excluded by dopplersonography) were prospectively
studied by transthoracic and transesophageal contrast echo and phlebogra-
phy if PFO was present.
Results: 220 pts, 136 men (60 ± 15 years) were studied. In 140 of 220 pts
neuroimaging showed evidence of manifest stroke. TEE identified a poten-
tial cardiac source of embolism (left atrial thrombus [lAT], PFO, atrial septal
aneurysm [ASA], spontaneous contrast [sq, endocarditic valve lesions, mi-
tral valvular disease [MVDj and prosthetic head valves) in 43% of pts com-
pared with only 18% by TIE (p < 0.01). TEE was especially superior com-
pared to TIE for identifying LAT (10 versus 0 pts), SC (26 vs 6 pts), PFO
associated with ASA (16 vs 6 pts) and PFO alone (34 vs 20 pts). Phlebogra-
phy was performed in 50 pts with PFO. Of those pts 32 showed brain infarct
2: 1 cm diameter on neuroimaging, 18 pts had TIA. Phlebography revealed
clinically silent DVT only in pts with brain infarct (4 cases, 12.5%), no pt with
TIA had positive phlebography.
Conclusion: In this prospective study TEE detected significantly more po-
tential sources of embolism than TIE; moreover, phlebography in the pres-
ence of PFO and a clear-cut ischemic brain lesion on neuroimaging revealed
a 12.5% incidence of clinically unsuspected deep venous thrombosis. These
findings strongly suggest paradoxical embolism as an important mechanism
of stroke and support phlebography to define the relevance of PFO in the
stepwise work-up of pts with suspected cardiogenic stroke.
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Transesophageal Echocardiographic Evaluation of
Patients with Cryptogenic Stroke: Is Transthoracic
Echocardlography Helpful?
Barbara A. Pisani, Kwame O. Akosah, Christine Maxine, Walter Paulsen, Pramod
K. Mohanty. McGuire VA Medical Center and Medical College of Virginia, Richmond,
VA
Approximately 30--40% of ischemic strokes are believed to be cardiogenic
in origin. Despite its poor sensitivity transthoracic echocardiography (TIE) is
widely used to rule out cardiac source of emboli. Recently transesophagel
echocardiography (TEE) has shown higher sensitivity for detecting potential
sources of embolic stroke. However, the extent to which TEE findings alter
the initial treatment plan is unclear. We evaluated 112 patients who were
referred for TIE to rule out cardiac sources of stroke by both TIE and TEE.
Nineteen (17%) had a positive TIE compared to 64 (57%) with positive TEE.
In addition, 11 of the 64 (17%) with abnormal TEE had findings which clearly
redirected the treatment plan (myxoma = 4; thoracic aortic mass = 1; native
valve vegetation = 1; prosthetic valve vegetation = 1; valvular masses = 3).
One patient whose TIE was interpreted as left atrial ILA) myxoma had atrial
septal aneurysm (ASA) byTEE. This ASA protruded into the lA and simulated
as a "mass" on the TTE. A higher rate of detection of potential source for
emboli was noted by TEE compared to TIE for ASA (10 vs 4); left atrialllA)
and LA appendage thrombi (20 vs 3); lA myxoma (4 vs 2); vegetation (2 vs
1); patent foramen ovale (4 vs 0); spontaneous echo contrast effect (11 vs 1)
and aortic debris (10 vs 0). These observations suggest increased ability of
TEE in the detection of potential cardiac sources of emboli with significant
impact on the treatment strategy. Whether TEE should be the initial choice
of test in patients with suspected systemic emboli remains to the defined.
Implantable Cardioverter Defibrillators:
Socia-Economic Factors
Tuesday, March 21,1995,8:30 a,m.-10:00 a.m.
Ernest N. Morial Convention Center, Room 6
8:30
1736-1 I Driving Safety in Patients with Implantable
Cardioverter-Defibrillators: A Single Center
Experience
Edward T Keelan, Anwer Dhala, Jasbir Sra, Kathi Axtell, Cheryl Maglio,
Mohammad R. Jazayeri, Zalmen Blanck, Sanjay Deshpande, Michael Biehl,
Masood Akhtar. Sinai Samaritan/Sf. Luke's Medical Center, Milwaukee, WI
There are as yet no clear guidelines regarding driving after cardioverter-
defibrillator (ICD) implantation. At this Institution, depending on their mode
of presentation patients (Pts) are advised to abstain from driving for 1-3
months after ICD implantation. Those without any syncopal episodes are
then allowed to drive if otherwise fit. To assess the safety of this approach,
we conducted a retrospective databank analysis of 635 Pts (508 males) of
mean age 62.5 ± 11.0 yrs who have been followed for a mean of 3.2 ± 2.4 yrs
(range 3 mth - 12yrs). Follow-up is complete on 629 Pts. The baseline char-
acteristics were: coronary artery disease in 80.5%, mean ejection fraction
33 ± 14% (n = 603) and 92.8% were in NYHA Class I or II. The presenting
arrhythmia was unstable VTNF in 55.5%, stablelnonsustained VT in 32.3%,
and was undocumented in 12.2%. We reviewed details on all Pts who had
had syncopal shocks (SS) or sudden cardiac death. There were 49 Pts who
had SS; lOaf these had 2:2 S5. The mean time to first SS was 18.8 ± 17.1
months after ICD implant. Only 1 Pt had a SS while driving (66 months after
first ICD implant); this did not result in a collision. There were 127 deaths
of which 22 were classified as sudden cardiac death. One Pt died suddenly
while driving 3 months post implant but did not cause injury to anyone else.
Conclusion; In this series, motor vehicle accidents resulting from syncopal
ICD shocks or sudden death occurred rarely. These results suggest that the
majority of Pts can be safely permitted to drive 1-3 months after ICD implant.
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1736-21 Should Patients be Permitted to Drive After
Cardioverter Defibfillator Implantation?
Hans-Joachim Trappe, Werner Schahl, Paul Wenzlaff. University Hospital Hannover,
Germany
It is unclear whether patients should be permitted to drive after cardioverter
defibrillator (ICD) implantation, or not. Therefore, questionnaires regarding
driVing have been completed by 162 patients (pts) who underwent ICD im-
plantation between 1/84 - 8/94. The mean follow-up of the pts population
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was 27 ± 10 months «1-114 months). In all pts, driving habits, ICD dis-
charges and accident occurrence were evaluated, all pts were seen in the
outpatient clinic every two months.
Results: No change in driving habits after ICD implantation was reported
by 140 pts (86%) group 1 (Gl). while the remaining 22 pts (14%) group 2 (G2)
showed modifications. During the follow-up lCD-discharges (D) occurred in
99/162 pts (61 %), in 84 pts (63%) in Gl and in 15 pts (70%) in G2. There
was a mean incidence of 18 lCD-discharges per pt in Gl and 20 ICD-D/pt in
G2. ICD-D occurred in 8 pts (5%) whilst driving a motor vehicle. 4 pts (2%)
reported on accident occurrence.
Conclusions: The incidence of ICD-D during driving is low and the major-
ity of pts do not modify their driving habits. An accident resulting from an
arrhythmic event appears to be rare and therefore, restriction of drivers' li-
censes after ICD implantation is not considered mandatory.
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Time-dependent multivariate analysis revealed ejection fraction and NYHA
class were the only variables independently related to time until death:
Conclusions: Sudden death and heart failure death occur at similar rates in
ICD pts. Ejection fraction and NYHA heart failure class are the most important
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1736-51 Quality of Life in Patients Receiving Implantable
Cardioverter Defibrillators Before Age 40
Anne M. Dubin, William P. Batsford, Richard J. Lewis, Lynda E. Rosenfeld. Yale
University. New Haven, CT
As the use of Implantable Cardioverter Defibrillators (ICD) increases, greater
numbers of young patients (pts) will receive these devices. Such pts may
have different expectations and requirements than older pts who more com-
monly receive ICDs. We investigated quality of life issues in all 25 pts fol-
lowed at Yale New Haven Hospital who were under age 40 years (13-40 y,
m = 28) at time of ICD placement. Mean time since ICD placement was 3.3
years. Four pts were excluded: 2 had devices explanted, and 2 died (1 from
sepsis and 1 from arrhythmia following ICD inactivation). Cardiac diagnoses
included: myocardial infarction m. long OT syndrome (6), cardiomyopathy
(6), and other (6).
Each pt received a modification of the New England Medical Center health
questionnaire; 16/21 responded (76%). Nine were women, and 10 were mar-
ried, 3 after ICD implantation. Highest education attained was high school
for 6 (37%), college for 7 {44%l. and graduate school for 3 (29%). Two pts
obtained graduate degrees and 4 women conceived after ICD implantation.
All delivered healthy infants including 1 whose ICD discharged during preg-
nancy. Ten pts were employed; 8 held the same job before and after ICD
placement. Two of the employed pts reported work difficulties: both reported
that they accomplished less than before, and worked less carefully.
All pts felt their health was good to excellent, with 6 reporting an improve-
ment in health since placement of the lCD, and 1 reporting a moderate de-
crease in overall health. All felt they were capable of the activities of daily
living, while 68% engaged freely in moderate physical activities. Only 31 %
felt able to fully participate in vigorous activities.
All pts felt they were average to very attractive. However, 63% worried
about how their clothes fit with the ICD and 68% worried about wearing
bathing suits (89% of the women and 43% of the men). The ICD interfered
somewhat with social interactions in 75% of pts, and 50% aVOided SOCial
functions, while 50% worried about sexual encounters, and 44% avoided
these encounters.
Thus, even though these young pts have body image concerns and limit
their activities, they are productive, active members of society, justifying ag-
gressive medical therapy and social support.
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1736-41 Time Course of Sudden Death and Heart Failure
Death in Patients with Third Generation Implantable
Cardioverter-Defibrillators
Michaela. Sweeney, Mary L. Guy, Hasan Garan, Brian McGovern, Jeremy Ruskin.
Massachusetts General Hospital, Boston, MA
Thirty seven cardiac deaths (12.2%) occurred in 301 pts with third genera-
tion implantable cardioverter-defibrillators (ICD) during a mean followup of
26 ± 15 months. There were 17 (5.6%) heart failure deaths (HFD) and 20
(6.6%) sudden cardiac deaths (SCD). Baseline variables including age, gen-
der, cardiac diagnosis, index or induced arrhythmia, and left ventricular ejec-
tion fraction were similar for HFD and SCD; mean NYHA class at ICD implant
was lower in the SCD group (p = 0.001). Kaplan-Meier survival rates for each
group were not different (Figure, p = 0.22).
1736-31 Costs and Complications of Non-thoracotomy
Defibrillator Systems: Impact of Health Care
Financing Administration Guidelines
John M. Herre, Linette R. Klevan, Martha M. Tenzer, Lauren J. Raymond, Lenox
D. Baker, Robert C. Bernstein. Eastern Virginia Medical School and Sentara Norfolk
General Hospital, Norfolk, VA
Non-thoracotomy implantable defibrillator (ICD) systems have been shown
to have lower costs and fewer complications than thoracotomy systems. Re-
cent interpretation of Health Care Financing Administration regulations has
challenged reimbursement for investigational devices or combinations of
components not approved by the Food and Drug Administration ("off-label").
We compared the costs and complications associated with approved pulse
generatorllead systems (CPI1600/Endotak, CPl1705/Endotak and Medtronic
7217!Transvene, n = 136) with investigational and "off-label" systems (CPI
1625/Endotak, CPI 1715/Endotak, Medtronic 7219!Transvene and Ventritex
Vl00 or V110/TVL and Vl00/Endotak, n = 79). Age [63 ± 12 years versus
63 ± 11 years (mean ± SD)I and ejection fraction (31 ± 15% versus 31 ±
11 %) were similar for patients with approved and investigational systems,
respectively. However, total hospital charges including preoperative care and
evaluation, implant procedure and hardware, postoperative testing and re-
visions were $64 ± 19,000 for approved devices versus $57 ± 16,000 for
non-approved devices (p = 0.02) despite higher overall costs of newer pulse
generators and leads. Total length of stay was 17 ± 10 days versus 14 ± 8
days (p = 0.03) and complications including lead dislodgement, increased
defibrillation threshold, hematoma and infection were 25/136 versus 4/77 (p
< 0.005)for approved and investigational or "off-label" systems, respectively.
Based on data provided by the manufacturers, anticipated average battery
longevity is 3.8 years for approved systems and 5.5 years for investigational
or "off-label" systems.
Conclusions: The prudent use of current investigational or "off-label" non-
thoracotomy ICD systems is more cost-effective and is associated with
fewer complications than approved ICD systems. When increased battery
longevity 'IS cons'ldered, long term costs of non-thoracotomy ICD therapy
may be improved dramatically with the use of investigational or "off-label"
systems. Review of reimbursement regulations may be warranted.
